Target ALS, New York, NY (2026)

12/31/2025

More than a decade ago, Dan Doctoroff set out to change how ALS research gets done, because moving slowly was never an option.

He believed progress would only come if barriers were removed, data were shared, and scientists worked together with urgency and purpose. That belief became Target ALS.

Today, the impact of that vision is visible across the field. And we keep pushing progress forward, until we change what it means to receive an ALS diagnosis. Every contribution tonight helps accelerate the science that can change what an ALS diagnosis means.

If you’re able, there’s still time to be part of this moment.

Ending ALS starts with you.

Give before the deadline tonight: https://ow.ly/Rf3q50XQaq6

12/30/2025

Progress like this does not happen by chance. It happens because people choose to act.

In 2025, Target ALS accelerated discovery, expanded who can participate in research, and moved new therapeutic programs closer to reality. These milestones reflect what becomes possible when barriers fall and collaboration leads.

Ending ALS starts with you: your decision to support bold science, inclusive research, and a future where progress moves faster than this disease.

Be part of what comes next: https://ow.ly/sgcZ50XQc28

12/29/2025

The ALS Global Research Initiative (AGRI) is advancing one of the most comprehensive efforts ever undertaken to understand ALS by integrating global study sites, in-community pop-up clinics, biosamples, clinical data, and cutting-edge scientific approaches to reveal how this disease develops and progresses.

And behind every participant enrolled, every sample processed, and every dataset shared is the support that makes this work possible.

These dollar handles highlight just a few of the real costs behind conducting AGRI, from reimbursing participants for critical contributions to funding genetic sequencing and sustaining international study sites over an entire year.

This is how deeper understanding takes shape.
This is how future treatments begin.

Give today because ending ALS starts with the research you help make possible: https://ow.ly/wMMg50XQajP

12/28/2025

To change the future of ALS, we have to understand it more deeply than ever before.

Through our ALS Global Research Initiative (AGRI), Target ALS is conducting the most comprehensive and diverse natural history study for ALS in the world. We’ve expanded to 14 active sites this year across three continents and are enrolling participants who reflect the true breadth of the ALS community.

With 34% of participants from diverse backgrounds (compared to just 5% in other studies), more than 23,000 biofluid vials available, and thousands of vials already distributed to researchers, we’re building the foundation of data and biosamples needed to accelerate the development of effective biomarkers and treatments.

This is what it looks like to conduct research that is global, inclusive, and built for impact.

Ending ALS starts with understanding and with everyone who chooses to play their part.

Join us to fuel this work: https://ow.ly/PuJZ50XP8gw

12/26/2025

Thanks to this community, we are thrilled to announce that we reached our $500,000 goal!

This milestone reflects the generosity, trust, and belief of a community dedicated to advancing ALS research. Every gift will power progress across our fund-enable-conduct model, and we are deeply grateful to each person who made this possible.

Because the work is far from finished, we are extending our goal to $700,000. Make a gift today to sustain the momentum you helped create as we push progress forward and work to change what it means to receive an ALS diagnosis.

Ending ALS starts with you: https://ow.ly/VlIh50XOrA8

12/24/2025

Happy Holidays from all of us at Target ALS.

As we look back on the past year, we’re grateful for the scientists, clinicians, caregivers, families, partners, and supporters who make this community so strong.

Your commitment fuels collaboration, sparks new ideas, and brings hope to everyone impacted by ALS.

Wishing you a peaceful holiday season and a hopeful start to the new year.

Thank you for being part of this movement.

12/23/2025

What if a “fingerprint” could help diagnose and track ALS?

At URI, Dr. Riccardo Sirtori is helping answer that question through biosensing technology. His team is developing a biosensor that captures a molecular profile, or “fingerprint,” from patient samples rather than relying on a single molecule to act as a biomarker for ALS. Using the biosensor, the team created a machine-learning model that was able to classify ALS versus control samples at high accuracy. This work is made possible by deep collaboration across engineering, neuroscience, and machine learning, and access to Target ALS samples and data.

“For us, collaboration is fundamental,” he shared. It’s the foundation of discoveries that could one day transform how ALS is detected, monitored, and understood.

And it’s a reminder that progress doesn’t start in one lab or with one idea. It starts when people choose to support research, share data openly, and work together toward something bigger.

Ending ALS starts with the supporters who make progress possible, and with the researchers who turn that support into discovery.

Read more: https://www.targetals.org/2025/11/12/biosensers-als-research/

12/23/2025

Last week, we shared that a generous anonymous couple stepped forward to match every gift from $100,000 to $200,000 of our $500,000 goal, and this community answered. Together, we unlocked the match and went beyond it, proving what’s possible when people rally around progress.

Thank you to everyone who made this moment real. There is still time to give, and every gift helps push ALS research forward, accelerate discovery, and move us closer to changing what it means to receive an ALS diagnosis.

Help build a world where : https://ow.ly/y4Lg50XNtA3

12/22/2025

Ending ALS starts with one decision: to give.

When you donate to Target ALS, your gift doesn’t sit still.

It moves through our Innovation Ecosystem – funding bold ideas, enabling researchers with the tools and data they need, and conducting the largest and most inclusive ALS research initiative to date. Our ecosystem drives collaboration across disciplines so discoveries can move faster.

By removing barriers like siloed research and bureaucratic red tape, we help the best ideas travel further: from early insight to real-world impact.

This is the chain of impact behind every gift, and this is how progress accelerates.

Make your decision count. Give today: https://ow.ly/VtrQ50XNp2T

12/20/2025

A meaningful milestone for global ALS research.

Our first participant has officially been enrolled at the Target ALS Global Natural History Study site in Israel, marking an important expansion of this worldwide effort. Across regions and borders, people living with and healthy volunteers are stepping forward to contribute data and biofluid samples that drive discovery and deepen our understanding of the disease.

We are incredibly grateful to each participant who makes this work possible. Their involvement is helping shape the most comprehensive and inclusive collection of ALS samples and data, moving us closer to changing what it means to receive an ALS diagnosis.

Learn more about the ALS Global Research Initiative (AGRI):
https://www.targetals.org/agri/

12/19/2025

A leader with vision. A force for change.

Dan Doctoroff has spent his life transforming possibility into progress. From the redevelopment of the World Trade Center site to projects like Hudson Yards, the High Line, and Brooklyn Bridge Park, his work reshaped New York City and redefined what bold leadership can achieve.

But nothing prepared him for the moment ALS entered his own life, the same disease that both his father and uncle battled with. What followed wasn’t resignation, it was resolve.

Dan founded Target ALS to change the trajectory of this disease for every family that will face it. By opening access, breaking down silos, and empowering scientists around the world, he helped build an engine for discovery to move faster than ALS itself.

His story is a reminder that progress begins with people who choose to act and people who believe that a different future is worth fighting for.

Ending ALS starts with people who choose action. It starts with all of us.

Be the reason progress doesn’t stop when you make a gift that goes 2X as far: https://ow.ly/oVpy50XMEq7

Video courtesy of ALS United Greater New York

12/18/2025

Before ALS touched his own life, Target ALS founder Dan Doctoroff already had a reputation. As Mike Bloomberg tells it, Dan was the person who never left the room until you said yes.

They spent years building things together in city government and at Bloomberg, sharing big ambitions and bigger ideas, and even laughing their way through the ALS Ice Bucket Challenge long before any of them knew what the future would hold.

So when Dan turned that same determination toward accelerating ALS research, Mike knew exactly what to do. He said yes. And chose to play a part in helping drive the breakthroughs that will change what it means to be diagnosed with ALS.

And now, this story continues with all of us. It starts with every person who believes science should move faster than this disease. It starts with those who give, who advocate, who share, who refuse to accept the status quo. It starts with a community that chooses hope and turns it into action.

Your support fuels the next discovery, the next trial, the next breakthrough.

Be part of what comes next.
Ending ALS starts with you.

Make a gift before the year ends: https://ow.ly/3vE750XLb6h

Bloomberg Bloomberg Philanthropies

Target ALS

12/31/2025

12/30/2025

12/29/2025

12/28/2025

12/26/2025

12/24/2025

12/23/2025

12/23/2025

12/22/2025

12/20/2025

12/19/2025

12/18/2025

Address

Telephone

Website

Alerts

Shortcuts

Featured

Share

Category